Greenwich Earnings per Diluted Share Trend from 2010 to 2022

GLSI
 Stock
  

USD 9.70  0.18  1.82%   

Greenwich Lifesciences Earnings per Diluted Share are increasing over the last several years with slightly volatile swings. Earnings per Diluted Share are predicted to flatten to -0.38. During the period from 2010 to 2022 Greenwich Lifesciences Earnings per Diluted Share regressed destribution of quarterly values had mean deviationof 3.28 and mean square error of  5.21. The current Consolidated Income is estimated to decrease to about (4.9 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (4.9 M).
  
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich main balance sheet or income statement drivers, such as Operating Expenses of 4.1 M, Research and Development Expense of 3.1 M or Selling General and Administrative Expense of 992.8 K, as well as many exotic indicators such as Book Value per Share of 2.24, Current Ratio of 76.24 or Debt to Equity Ratio of 0.0151. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules. It can also supplement various Greenwich Lifesciences Technical models . Please check the analysis of Greenwich Lifesciences Correlation against competitors.

Greenwich Lifesciences Quarterly Earnings per Diluted Share

(0.15)

Greenwich Earnings per Diluted Share Breakdown

Showing smoothed Earnings per Diluted Share of Greenwich Lifesciences with missing and latest data points interpolated. Earnings per diluted share as calculated and reported by the company. Approximates to the amount of Net Income Common Stock for the period per each [SharesWADil] after adjusting for [ShareFactor]..Greenwich Lifesciences' Earnings per Diluted Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Greenwich Lifesciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (0.27) X10 Years Trend
Increasing
Slightly volatile
   Earnings per Diluted Share   
Share
       Timeline  

Greenwich Earnings per Diluted Share Regression Statistics

Arithmetic Mean(5.95)
Coefficient Of Variation(62.46)
Mean Deviation 3.28
Median(8.32)
Standard Deviation 3.72
Sample Variance 13.80
Range 8.12
R-Value 0.81
Mean Square Error 5.21
R-Squared 0.65
Significance 0.00082129
Slope 0.77
Total Sum of Squares 165.64

Greenwich Earnings per Diluted Share History

2019 -1.52
2020 -0.2
2021 -0.35
2022 -0.38

About Greenwich Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Greenwich Lifesciences income statement, its balance sheet, and the statement of cash flows. Greenwich Lifesciences investors use historical funamental indicators, such as Greenwich Lifesciences's Earnings per Diluted Share, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences investors may use each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Greenwich Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Greenwich Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Earnings per Diluted Share(0.35) (0.38) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-4.6 M-4.9 M
Earnings before Tax-4.6 M-4.9 M
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Greenwich Lifesciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of Greenwich Lifesciences Correlation against competitors. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
113.4 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.